Table 1 Baseline characteristic of 53 patients with multiple myeloma planned for salvage high-dose melphalan with ASCT at first symptomatic relapse after initial ASCT

From: Salvage bortezomib–dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial

Baseline characteristics

 

Median

Range

Age (years)

60

36–70

Gender

Female 21 (40%)

 
 

Male 32 (60%)

 

M-protein

IgG 36 (73%)

 
 

IgA 9 (18%)

 
 

IgD 1 (2%)

 
 

Light chain only three (6%)

 
 

Unknown 4

 

Initial induction

 VAD

10

 

 CTX/Dex

43

 

 Maintenance

  

 IFNa

7

 

 None

46

 

PFS (I) (months)

25.3

3.5–112.3

TNT (I) (months)

29.1

4.8–112.3

ISS

I 19 (36%)

 
 

II 12 (23%)

 
 

III 10 (19%)

 
 

NA 12 (23%)

 
  1. Abbreviations: ASCT=autologous stem cell support; CTX/Dex=cyclophosphamide and dexamethasone (two series followed by CTX-G-CSF for mobilizing peripheral stem cells); ISS=international staging system; PFS (I)=progression-free survival after initial ASCT; TNT (I)=time to next treatment after initial ASCT; VAD=vincristin, adriamycin, dexamethasone (three series followed by CTX-G-CSF for mobilizing peripheral stem cells).
  2. aInterferon 2α maintenance three times a week.
Back to article page